a Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou University Second Clinical Medical College , Lanzhou , Gansu , China.
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3286-3296. doi: 10.1080/21691401.2019.1648283.
The long-term prognosis of patients with lung cancer remains poor and thus it is imminent to further elucidate the molecular mechanism for the oncogenesis of lung cancer. In this study, we observed that surfactant protein C (SFTPC) expression was downregulated in human lung adenocarcinoma tissues and cell lines, and low SFTPC expression correlated with poor overall survival of lung adenocarcinoma patients. Moreover, we found that overexpression of SFTPC could inhibit lung cancer cell proliferation and , but downregulation of SFTPC showed the opposite results. Besides, it was observed that miR-629-3p expression was upregulated in human lung adenocarcinoma tissues and cell lines. More importantly, we found that miR-629-3p could downregulate SFTPC expression by directly binding to the SFTPC 3'-UTR and inhibit the regulatory effect of SFTPC on lung adenocarcinoma cell proliferation. In conclusion, these data suggested that miR-629-3p-meditated downregulation of SFTPC may promote lung adenocarcinoma progression.
肺癌患者的长期预后仍然较差，因此迫切需要进一步阐明肺癌发生的分子机制。在这项研究中，我们观察到表面活性蛋白 C（SFTPC）在人肺腺癌组织和细胞系中的表达下调，并且 SFTPC 低表达与肺腺癌患者的总生存率差相关。此外，我们发现 SFTPC 的过表达可以抑制肺癌细胞的增殖和迁移，而 SFTPC 的下调则显示出相反的结果。此外，还观察到 miR-629-3p 在人肺腺癌组织和细胞系中表达上调。更重要的是，我们发现 miR-629-3p 可以通过直接结合 SFTPC 的 3'-UTR 来下调 SFTPC 的表达，并抑制 SFTPC 对肺腺癌细胞增殖的调节作用。总之，这些数据表明，miR-629-3p 介导的 SFTPC 下调可能促进肺腺癌的进展。
